American BMS announced the purchase of a cancer drug developer for $5.8 billion
[ad_1]
The American pharmaceutical company Bristol Myers Squibb (BMS) has entered into an agreement to purchase Mirati Therapeutics, which is developing cancer drugs. reported manufacturer’s press service.
Under the agreement, BMS will buy Mirati for $58 per share, representing $4.8 billion for the entire company. At the same time, Mirati shareholders will be entitled to a contingent value (CVR) of $12 per share, or $1 billion in addition to the transaction.
The boards of directors of both companies approved the merger. The transaction is expected to close in the first half of 2024, subject to receipt of necessary regulatory approvals.
It is noted that as a result of the transaction, BMS will receive into its portfolio the drug for the treatment of lung cancer Krazati, which has already been approved by the regulator. At the same time, the company will gain access to several promising clinical assets in the field of oncology treatment.
BMS was founded in 1887 and is one of the largest pharmaceutical companies in the world, with its headquarters in New York. The company previously operated in Russia. After the start of the special operation in Ukraine in February 2022, it became known that BMS decided leave Russia and transfer your business to a partner in Central and Eastern Europe – the Swiss pharmaceutical company Swixx BioPharma.
[ad_2]
Source link
